(Q56656388)

6

Jacques Izopet

0 references

Nassim Kamar

1

Nassim Kamar

0 references

Samreen Ijaz

Samreen Ijaz

5

1 reference

ORCID Public Data File 2021

Florence Legrand-Abravanel

3

Florence Legrand-Abravanel

0 references

Richard P Bendall

2

Richard Bendall

0 references

author name string

Ning-Shao Xia

4

0 references

Harry R Dalton

A novel virus in swine is closely related to the human hepatitis E virus

7

0 references

language of work or name

English

0 references

publication date

June 2012

0 references

30 June 2012

0 references

published in

The Lancet

0 references

volume

379

0 references

issue

9835

0 references

page(s)

2477-2488

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus: animal reservoirs and zoonotic risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Sequence data suggests big liver and spleen disease virus (BLSV) is genetically related to hepatitis E virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

A novel member of the family Hepeviridae from cutthroat trout (Oncorhynchus clarkii).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Expression and self-assembly of empty virus-like particles of hepatitis E virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Heparan sulfate proteoglycans are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Spatial configuration of hepatitis E virus antigenic domain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

ORF3 protein of hepatitis E virus is essential for virion release from infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Release of genotype 1 hepatitis E virus from cultured hepatoma and polarized intestinal cells depends on open reading frame 3 protein and requires an intact PXXP motif

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Structure of the hepatitis E virus-like particle suggests mechanisms for virus assembly and receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Structural basis for the neutralization and genotype specificity of hepatitis E virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E Virus (HEV) strains in serum samples can replicate efficiently in cultured cells despite the coexistence of HEV antibodies: characterization of HEV virions in blood circulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Development and evaluation of an efficient cell-culture system for Hepatitis E virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Development and characterization of a genotype 4 hepatitis E virus cell culture system using a HE-JF5/15F strain recovered from a fulminant hepatitis patient.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E: an emerging infection in developed countries.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

First isolation of hepatitis E virus genotype 4 in Europe through swine surveillance in the Netherlands and Belgium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Zoonotic transmission of hepatitis E virus from deer to human beings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Pig liver sausage as a source of hepatitis E virus transmission to humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Detection of a novel hepatitis E-like virus in faeces of wild rats using a nested broad-spectrum RT-PCR.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Analysis of the full-length genome of a hepatitis E virus isolate obtained from a wild boar in Japan that is classifiable into a novel genotype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

A novel genotype of hepatitis E virus prevalent among farmed rabbits in China

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus genotype 3 diversity, France

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Evolutionary history and population dynamics of hepatitis E virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Possible risk factors for the transmission of hepatitis E virus and for the severe form of hepatitis E acquired locally in Hokkaido, Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Profile of acute infectious markers in sporadic hepatitis E.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Serological response to hepatitis E virus genotype 3 infection: IgG quantitation, avidity, and IgM response.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus (HEV) capsid antigens derived from viruses of human and swine origin are equally efficient for detecting anti-HEV by enzyme immunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Putative neutralization epitopes and broad cross-genotype neutralization of Hepatitis E virus confirmed by a quantitative cell-culture assay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Good performance of immunoglobulin M assays in diagnosing genotype 3 hepatitis E virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Serologic assays specific to immunoglobulin M antibodies against hepatitis E virus: pangenotypic evaluation of performances

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Use of serological assays for diagnosis of hepatitis E virus genotype 1 and 3 infections in a setting of low endemicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Safety and efficacy of a recombinant hepatitis E vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Immunologically silent autochthonous acute hepatitis E virus infection in France

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus antibodies in blood donors, France

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Standardization of hepatitis E virus (HEV) nucleic acid amplification technique-based assays: an initial study to evaluate a panel of HEV strains and investigate laboratory performance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus transmission to a volunteer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Viremia, Fecal Shedding, and IgM and IgG Responses in Patients with Hepatitis E

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Persistent carriage of hepatitis E virus in patients with HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Specific cellular immune response in hepatitis E patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Evidence of hepatitis E virus exposure among seronegative healthy residents of an endemic area

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E epidemic, Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Novel risk factors associated with hepatitis E virus infection in a large outbreak in northern Uganda: results from a case-control study and environmental analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Acute viral hepatitis morbidity and mortality associated with hepatitis E virus infection: Uzbekistan surveillance data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E: an emerging awareness of an old disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Epidemic of hepatitis E in a military unit in Abbotrabad, Pakistan.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Association of hepatitis E virus with an outbreak of hepatitis at a military training camp in Nepal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Rates of hepatitis E virus infection and disease among adolescents and adults in Kathmandu, Nepal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus genotype diversity in eastern China

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Clinical characteristics and risk factors of sporadic Hepatitis E in central China

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E in the south west of France in individuals who have never visited an endemic area

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Phylogenetic and case-control study on hepatitis E virus infection in Germany

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E in new zealand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Acute hepatitis E infection acquired in California

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Distinct changing profiles of hepatitis A and E virus infection among patients with acute hepatitis, patients on maintenance hemodialysis and healthy individuals in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus in patients with unexplained hepatitis in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Autochthonous hepatitis E in Southwest England: a comparison with hepatitis A

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

The incidence of hepatitis E virus infection in the general population of the USA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Prevalence of anti-hepatitis E virus antibodies in French blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Bayesian estimation of hepatitis E virus seroprevalence for populations with different exposure levels to swine in The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

High prevalence of anti-hepatitis E virus antibodies in blood donors from South West France

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Is there evidence of recent hepatitis E virus infection in English and North Welsh blood donors?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Seroprevalence of hepatitis E virus infection, rural southern People's Republic of China

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus and the kidney in solid-organ transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E outbreak on cruise ship.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Indigenous hepatitis E virus infection in England: more common than it seems.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E autochthonous infection in chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Host risk factors and autochthonous hepatitis E infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

The role of hepatitis E virus testing in drug-induced liver injury.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Locally acquired hepatitis E in chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Relationship between pork consumption and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

National mortality rates from chronic liver disease and consumption of alcohol and pig meat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus and chronic hepatitis in organ-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Chronic hepatitis E with cirrhosis in a kidney-transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Chronic hepatitis E virus infection in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus as an emerging cause of chronic liver disease in organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E in an HIV-infected patient

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E Virus seroprevalence and chronic infections in patients with HIV, Switzerland.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Prolonged hepatitis E in an immunocompromised patient

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Persistent infection of hepatitis E virus transmitted by blood transfusion in a patient with T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Chronic hepatitis E virus infection: successful virologic response to pegylated interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus infection in patients infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E and jaundice in an HIV-positive pregnant woman

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Acute and chronic hepatitis E in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Neuralgic amyotrophy associated with hepatitis E virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Seizure associated with acute hepatitis E

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus and neurologic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Hepatitis E virus-induced neurological symptoms in a kidney-transplant patient with chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Acute pancreatitis: a rare complication of acute hepatitis E.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Severe thrombocytopenia associated with acute autochthonous hepatitis E

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Acute autochthonous hepatitis E in western patients with underlying chronic liver disease: a role for ribavirin?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Treatment of severe acute hepatitis E by ribavirin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Brief communication: case reports of ribavirin treatment for chronic hepatitis E.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Treatment of chronic hepatitis E in a patient with HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Definitive clearance of a chronic hepatitis E virus infection with ribavirin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Transfusion-associated hepatitis E, France

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Prevalence of hepatitis E virus in Chinese blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021

Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961849-7

7 January 2021